Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 28, 2013
Event: Entry into a Material Definitive Agreement (Asset Purchase Agreement).
Key Financial Metrics and Transaction Details
This filing reports a specific acquisition transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or debt levels are not disclosed in this document).
| Component | Details |
|---|---|
| Target | InaVein, LLC (Assets related to varicose vein treatment products) |
| Closing Date | August 28, 2013 |
| Cash Consideration | $2,125,000 (paid at closing) + $375,000 (payable after first anniversary) |
| Contingent Consideration | Up to $1,400,000 total based on sales performance and regulatory milestones |
- Year 1 Earn-out: 0.7x amount by which net sales exceed $2.5 million (capped at $500,000).
- Year 2 Earn-out: 0.7x amount by which net sales exceed the greater of $2.7 million or Year 1 actual sales (capped at $500,000).
- Regulatory Milestone: $400,000 if certain products are re-registered with the China Food and Drug Administration by August 31, 2014.
Material Changes and Agreements
The primary material change is the acquisition of InaVein's assets. Key contractual terms include:
- Non-Compete: InaVein is restricted from engaging in competitive activities and soliciting former employees for five years post-closing.
- Indemnification: Both parties are obligated to indemnify each other for breaches of representations, warranties, covenants, and specified liabilities.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the acquisition but does not provide specific forward-looking financial guidance or revenue projections within the text of the 8-K itself.
Risks and Contingencies:
- Regulatory Risk: A portion of the purchase price ($400,000) is contingent on successful re-registration of products with the China Food and Drug Administration by a specific deadline.
- Performance Risk: Significant contingent consideration depends on the acquired products meeting specific net sales thresholds in the first and second years post-acquisition.
Investor Verification Checklist
- Verify the full text of the Asset Purchase Agreement when filed in the Form 10-Q for the quarter ended September 30, 2013.
- Monitor the re-registration status of acquired products with the China Food and Drug Administration for the August 31, 2014 deadline.
- Track the net sales performance of the acquired InaVein products to determine the payout of the Year 1 and Year 2 earn-outs.
- Review the press release (Exhibit 99.1) for additional strategic context not detailed in the 8-K summary.